Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport
Related Experiment Video
Updated: Jul 16, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
J Sims-Mourtada1, J G Izzo, J Ajani
1Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Abstract:
A major obstacle to successful chemotherapy is intrinsic or acquired multi-drug resistance (MDR). The most common cause of MDR involves increased drug efflux from cancer cells mediated by members of the ATP-binding cassette (ABC) transporter family. The regulation of ABC transporters in the context of cancer is poorly understood, and clinical efforts to inhibit their function have not been fruitful. Constitutive activation of the Hedgehog (Hh) pathway has been shown to contribute to the growth and maintenance of various cancers. Here, we show that inhibition of Hh signaling increases the response of cancer cells to multiple structurally unrelated chemotherapies. We further show that Hh pathway activation induces chemoresistance in part by increasing drug efflux in an ABC transporter-dependent manner. We found that Hh signaling regulates the expression of the ABC transporter proteins multi-drug resistance protein-1 (MDR1, ABCB1, P-glycoprotein) and (BCRP, ABCG2), and that targeted knockdown of MDR1 and BCRP expression by small interfering RNA partially reverses Hh-induced chemoresistance. These results suggest that the Hh pathway may be a target to overcome MDR and increase chemotherapeutic response.
Insights
Inhibiting the Hedgehog (Hh) pathway enhances chemotherapy effectiveness by reducing multi-drug resistance (MDR) in cancer cells. Hh signaling increases drug efflux via ATP-binding cassette (ABC) transporters, contributing to MDR.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Multi-drug resistance (MDR) is a significant challenge in chemotherapy, often caused by increased drug efflux mediated by ATP-binding cassette (ABC) transporters.
- The regulation of ABC transporters in cancer and their role in MDR are not fully understood, limiting effective clinical strategies.
- Constitutive activation of the Hedgehog (Hh) signaling pathway is implicated in the growth and maintenance of various cancers.
Purpose of the Study:
- To investigate the role of Hedgehog (Hh) signaling in chemoresistance and explore its potential as a therapeutic target.
- To determine if Hh pathway activation influences the expression and function of ATP-binding cassette (ABC) transporters involved in multi-drug resistance (MDR).
Main Methods:
- Assessing the impact of Hh signaling inhibition on cancer cell response to various chemotherapies.
- Investigating the mechanism by which Hh pathway activation induces chemoresistance, focusing on drug efflux and ABC transporter activity.
- Analyzing the regulation of specific ABC transporters, including MDR1 (ABCB1) and BCRP (ABCG2), by Hh signaling.
- Utilizing small interfering RNA (siRNA) to knock down MDR1 and BCRP expression and evaluate its effect on Hh-induced chemoresistance.
Main Results:
- Inhibition of Hh signaling significantly improved cancer cell sensitivity to multiple chemotherapeutic agents.
- Hedgehog (Hh) pathway activation was found to induce chemoresistance, at least partially, by enhancing drug efflux dependent on ATP-binding cassette (ABC) transporters.
- Hh signaling was demonstrated to regulate the expression of key ABC transporters, namely multi-drug resistance protein-1 (MDR1, ABCB1) and Breast Cancer Resistance Protein (BCRP, ABCG2).
- Targeted knockdown of MDR1 and BCRP expression using small interfering RNA (siRNA) partially reversed the chemoresistance induced by Hh pathway activation.
Conclusions:
- The Hedgehog (Hh) signaling pathway plays a crucial role in mediating chemoresistance in cancer.
- Hh pathway activation contributes to multi-drug resistance (MDR) by upregulating ATP-binding cassette (ABC) transporters involved in drug efflux.
- Targeting the Hh pathway presents a promising strategy to overcome MDR and enhance the efficacy of chemotherapy in cancer treatment.
More Related Videos
Related Concept Videos
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Treatment Resistant Cancers
Hedgehog Signaling Pathway
Hedgehog Signaling Pathway
Carrier-Mediated Transport
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Nonlinear Pharmacokinetics: Role of Transporters
Polymorphisms occurring in drug transporters can alter...

